Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Share:
Related MDCO
Citi Sees Limited Sales For Blood-Clot Drug At The Medicines Company
FDA Advisory Committee Recommends Approval of The Medicines Company's Antiplatelet Therapy Cangrelor
Related BMY
Berenberg Initiates Bristol-Myers Squibb With Hold
Benzinga's Top Initiations
Merck got EU's CHMP (Investor's Business Daily)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News

 

Related Articles (MDCO + BMY)

Around the Web, We're Loving...